Skip to main content
An official website of the United States government

Lenvatinib Mesylate

Placeholder slot
 (len-VA-tih-nib MEH-zih-layt)

Lenvatinib mesylate works by blocking proteins that signal cancer cells to divide. It also blocks proteins that signal the growth of new blood vessels that tumors need to grow. Blocking these signals keeps cancer cells from growing. Lenvatinib mesylate is a type of targeted therapy drug called a kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily).

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Lenvatinib mesylate is approved to be used alone or with other drugs to treat:

Lenvatinib mesylate is also being studied in the treatment of other types of cancer.

More About Lenvatinib Mesylate

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Lenvatinib Mesylate - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Targeted Therapy to Treat Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Lenvatinib Mesylate - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: